PharmaCielo Ltd.
PCLOF
$0.0478
-$0.0067-12.29%
| Weiss Ratings | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.85 | |||
| Price History | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -22.02% | |||
| 30-Day Total Return | -28.66% | |||
| 60-Day Total Return | -33.05% | |||
| 90-Day Total Return | -34.34% | |||
| Year to Date Total Return | -15.40% | |||
| 1-Year Total Return | -54.82% | |||
| 2-Year Total Return | -66.76% | |||
| 3-Year Total Return | -91.88% | |||
| 5-Year Total Return | -88.71% | |||
| 52-Week High % Change | -78.27% | |||
| 52-Week Low % Change | 8.64% | |||
| Price | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.22 | |||
| 52-Week Low Price | $0.04 | |||
| 52-Week Low Price (Date) | Jan 02, 2025 | |||
| 52-Week High Price (Date) | Jun 06, 2024 | |||
| Valuation | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.16M | |||
| Enterprise Value | 23.33M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.06 | |||
| Earnings Per Share Growth | 1.97% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.09 | |||
| Price/Book (Q) | -1.44 | |||
| Enterprise Value/Revenue (TTM) | 12.24 | |||
| Price | $0.05 | |||
| Enterprise Value/EBITDA (TTM) | -5.65 | |||
| Enterprise Value/EBIT | -5.42 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 162.03M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 82 Richmond Street East Toronto, ON M5C 1P1 | |||
| Website | www.pharmacielo.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -225.93% | |||
| Profit Margin | -541.54% | |||
| Management Effectiveness | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.69% | |||
| Return on Equity | -- | |||
| Income Statement | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.90M | |||
| Total Revenue (TTM) | 1.90M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 18.30K | |||
| EBITDA (TTM) | -4.12M | |||
| EBIT (TTM) | -4.30M | |||
| Net Income (TTM) | -10.31M | |||
| Net Income Avl. to Common (TTM) | -10.31M | |||
| Total Revenue Growth (Q YOY) | 271.59% | |||
| Earnings Growth (Q YOY) | 5.83% | |||
| EPS Diluted (TTM) | -0.06 | |||
| EPS Diluted Growth (Q YOY) | 5.51% | |||
| Balance Sheet | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 18.70K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 2.58M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -5.62M | |||
| Current Ratio (Q) | 0.153 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 14.59M | |||
| Total Current Liabilities (Q) | 16.93M | |||
| Total Debt (Q) | 15.47M | |||
| Total Liabilities (Q) | 20.21M | |||
| Total Common Equity (Q) | -5.62M | |||
| Cash Flow | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 194.10K | |||
| Cash from Financing (TTM) | 2.19M | |||
| Net Change in Cash (TTM) | 2.20K | |||
| Levered Free Cash Flow (TTM) | -3.58M | |||
| Cash from Operations (TTM) | -2.39M | |||
